Table 1 Patient demographic and baseline clinical characteristics
n, % | Veliparib + FOLFIRI ± Bevacizumab (N = 65) | Placebo + FOLFIRI ± Bevacizumab (N = 65) | P-value |
|---|---|---|---|
Age, years, median (range) | 59 (26–84) | 64 (43–84) | 0.016a |
Age | 0.048b | ||
<65 years | 45 (69%) | 33 (51%) | |
≥65 years | 20 (31%) | 32 (49%) | |
Gender | – | ||
Male | 44 (68%) | 40 (62%) | |
Female | 21 (32%) | 25 (38%) | |
Race | – | ||
White | 62 (95%) | 64 (98%) | |
Black | 3 (5%) | 1 (2%) | |
Ethnicity | – | ||
Hispanic or Latino | 2 (3%) | 7 (11%) | |
Not Hispanic or Latino | 63 (97%) | 58 (89%) | |
World region | – | ||
North America | 8 (12%) | 9 (14%) | |
Rest of world | 57 (88%) | 56 (86%) | |
Bevacizumab use (actual) | – | ||
Received | 31 (48%) | 32 (49%) | |
Not received | 34 (52%) | 33 (51%) | |
ECOG Performance Status | – | ||
0 | 26 (40%) | 24 (37%) | |
>0 | 39 (60%) | 41 (63%) | |
Smoking status | – | ||
Current | 10 (15%) | 10 (15%) | |
Former | 16 (25%) | 26 (40%) | |
Never | 37 (57%) | 29 (45%) | |
Unknown | 2 (3%) | 0 | |
Number of metastatic sites | – | ||
1 | 44 (68%) | 42 (65%) | |
2 | 14 (22%) | 14 (22%) | |
3 | 4 (6%) | 4 (6%) | |
4 | 3 (5%) | 5 (8%) | |
Location of metastases | – | ||
Lung | 24 (37%) | 24 (37%) | |
Non-lung | 41 (63%) | 41 (63%) | |
Tumour resection history | – | ||
Yes | 36 (55%) | 39 (60%) |
